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REPLY
We thank Dr. Alfonso for his comments about our study (1). His
observations provide an opportunity: 1) to analyze the implications
of the procedural finding of balloon slippage in patients with
in-stent restenosis (ISR) treated by conventional balloon angio-
plasty; 2) to report whether a specific subgroup of patients
benefited from cutting balloon angioplasty; and 3) to discuss the
possible benefit of lesion pre-dilation using the cutting balloon in
patients with ISR treated with drug-eluting stenting.
First, analysis of the Restenosis Cutting Balloon Evaluation
Trial (RESCUT) database shows that in the group treated with
conventional balloon angioplasty, balloon slippage was associated
with a higher percentage, although not statistically significant, of
residual dissections (11.1% vs. 6,9%; p  0.35), and a higher
percentage of additional stent implantation (9.5% vs. 3.5%; p 
0.21) mainly due to type D, E, and F dissections. However,
recurrent restenosis rate at six months was not higher when balloon
slippage was observed.
Second, the analysis performed with the multivariate technique
to determine whether any specific subset of ISR patients/lesions
benefited from the cutting balloon treatment (i.e., short vs. long
lesions, small vs. large vessel, diabetics vs. nondiabetics, short time
vs. long time by previous implanted stent, first vs.1 prior ISR on
the same vessel) did not uncover any significant effect.
Third, although a recent study failed to demonstrate long-term
benefits after the use of cutting balloon in ISR patients undergoing
adjunctive gamma brachytherapy (2), in the Registry Novoste
(RENO) (3) where brachytherapy was performed using beta-
radiation, pretreatment with cutting balloon significantly reduced
six-month target-vessel revascularization compared with conven-
tional angioplasty (10.2% vs. 16.6%; p  0.04).
However, we do not believe that the use of cutting balloon will
translate into clinical or angiographic benefit for patients with ISR
treated with drug-eluting stents (DES), as a result of the proce-
dural differences in the treatment of ISR using adjunctive brachy-
therapy compared with restenting with a DES. In the first case,
before adjunctive brachytherapy, it is recommended to optimally
treat ISR by conventional/cutting balloon angioplasty or atherec-
tomy, avoiding additional stenting to reduce the risk of late stent
thrombosis, whereas in the case of restenting with a DES, an
optimal balloon pretreatment of ISR is not necessary, nor is the use
of cutting balloon to avoid balloon slippage, because the operator
can reduce the risk of vessel injury at the stent edges, even in the
event of balloon slippage, by simply predilating the ISR lesion
using an undersized noncompliant conventional balloon.
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Rate Control in Atrial Fibrillation
We read with great interest the substudy of the Atrial Fibrillation
Follow-up Investigation of Rhythm Management (AFFIRM)
investigators on the approaches to control rate in atrial fibrillation
(AF) (1). Recent studies show that rate control may be adopted as
first-choice therapy in a variety of patients with AF (2,3). The
optimal level of heart rate during AF is, however, still unknown.
In the AFFIRM study, in accordance with the guidelines (4), a
strict rate-control approach was applied that includes a resting
heart rate 80 beats/min and either a 6-min walk test heart rate
110 beats/min or a mean heart rate on a 24-h Holter recording
100 beats/min, in combination with a maximum heart rate
110% of predicted maximum heart rate. The present study shows
that this (strict) rate-control approach can be successfully achieved
in two-thirds of the patients and that, in line with previous data,
beta-blockers are most effective to accomplish this goal (5). Serious
adverse effects were uncommon. However, to obtain adequate rate
control, atrioventricular node ablation and pacemaker implantation
was performed in 108 of the 2,027 patients (5.3%), and an
additional 147 patients (7.3%) had a pacemaker implanted for
symptomatic bradycardia. In comparison, in the RAte Control
versus Electrical cardioversion (RACE) study, a more lenient
rate-control approach was followed (resting heart rate 100
beats/min) (3). In that study, 46% of the patients were treated with
a beta-blocker. Severe drug adverse effects were also rare (0.8%). In
contrast to the AFFIRM study, however, a pacemaker was
implanted in only 3 of the 256 patients (1.2%, all after atrioven-
tricular node ablation).
Unfortunately, the AFFIRM investigators give no data on the
influence of the level of rate control on mortality and morbidity.
Therefore, it still, remains unknown whether strict rate control is
associated with an improved prognosis. To answer the question of
which approach to rate control is most effective we will start the RAte
Control Efficacy in permanent atrial fibrillation study (RACE II).
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The AFFIRM Study: Approaches
to Control Rate in Atrial Fibrillation
The optimal heart rate for patients with atrial fibrillation (AF)
remains unclear; current guidelines are primarily based on clinical
experience (1). Recent randomized studies suggest combining
beta-blockers or calcium channel blockers with digoxin to achieve
better rate control at rest and during exercise (2–4). However, I
believe clarification of the “approach to control rate in AF” by the
Atrial Fibrillation Follow-up Investigation of Rhythm Manage-
ment (AFFIRM) investigators (4) is justified.
A total of 2,027 patients were randomized to the rate control
arm of the AFFIRM trial between 1995 and 1999. Of these, 248
crossed over to the rhythm-control group due to “uncontrolled
symptoms” and 108 underwent AV nodal ablation due to failure of
pharmacologic therapy. Rate-control data at rest are available in
only 740 (36.5%) patients, which deteriorates further to 361
(17.8%) if data regarding heart-rate control during exercise are
desired.
This relative lack of data may be explained by the fact that 1,055
(52%) patients were in sinus rhythm at the time of randomization.
The proportion of those in the rate-control group who maintained
sinus rhythm during follow-up is unclear. Published data for the
entire trial population suggest a similar number (49%) remaining
in sinus rhythm at study end.
Therefore, the majority of data on rate control of AF comes
from a minority of patients randomized to a rate-control strategy.
Because of the nature of data collection (only patients with AF at
the time of assessment were selected for analysis), care should be
taken in interpreting these results. The data predominantly repre-
sent patients with persistent and permanent AF and significantly
underrepresent those with paroxysmal AF.
It is difficult to make conclusions on the control of ventricular
rate during paroxysms of AF from this study, the occurrence of
which greatly depends on variations of the autonomic tone (5).
*Rhidian J. Shelton, MBChB, MRCP (UK)
*Academic Cardiology
University of Hull
Castle Hill Hospital
Cottingham
Kingston-upon-Hull
HU16 5JQ
United Kingdom
E-mail: rhidianshelton@btopenworld.com
doi:10.1016/j.jacc.2004.09.025
REFERENCES
1. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines
for the management of patients with atrial fibrillation: executive
summary. A report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines and the European
Society of Cardiology Committee for Practice Guidelines and Policy
Conferences (Committee to Develop Guidelines for the Management
of Patients With Atrial Fibrillation) developed in collaboration with the
North American Society of Pacing and Electrophysiology. Circulation
2001;104:2118–50.
2. Farshi R, Kistner D, Sarma JS, Longmate JA, Singh BN. Ventricular
rate control in chronic atrial fibrillation during daily activity and
programmed exercise: a crossover open-label study of five drug regi-
mens. J Am Coll Cardiol 1999;33:304–10.
3. Khand AU, Rankin AC, Martin W, Taylor J, Gemmell I, Cleland JG.
Carvedilol alone or in combination with digoxin for the management of
atrial fibrillation in patients with heart failure? J Am Coll Cardiol
2003;42:1944–51.
4. Olshansky B, Rosenfeld LE, Warner AL, et al., for the AFFIRM
investigators. The Atrial Fibrillation Follow-up Investigation of
Rhythm Management (AFFIRM) study: approaches to control rate in
atrial fibrillation. J Am Coll Cardiol 2004;43:1201–8.
5. Bettoni M, Zimmermann M. Autonomic tone variations before the
onset of paroxysmal atrial fibrillation. Circulation 2002;105:2753–9.
REPLY
We thank Dr. Van Gelder and colleagues and Dr. Shelton for their
interest in our study (1). We agree with Dr. Van Gelder and
colleagues that the optimal heart rate in atrial fibrillation (AF)
during rest and exercise is unknown. Perhaps minimal effort to
achieve rate control during AF is sufficient. However, absence of
adequate rate control can lead to adverse consequences such as
tachycardia-induced cardiomyopathy. Our Atrial Fibrillation
Follow-up Investigation of Rhythm Management (AFFIRM)
substudy was not designed to evaluate the mortality and morbidity
of inadequate rate control; thus, we cannot comment on these end
points.
Both ablation of the atrioventricular junction and pacemaker
insertion were allowed “innovative” therapies in the AFFIRM
study, and they may have contributed to the relatively frequent use
of this approach. Furthermore, attempting to achieve more “strin-
gent” rate control may have led to more symptomatic drug-induced
bradycardia and subsequent pacemaker insertion in the AFFIRM
study, compared to the more “lenient” criteria used in the RAte
Control versus Electrical cardioversion (RACE) study. However,
the patient population in the AFFIRM study was not directly
comparable to that in RACE, and pacemaker implantation per
capita in the U.S. is higher than in Europe. These factors may have
influenced the differences between these two studies.
We agree that a long-term, prospective, randomized trial would
be useful. We applaud Dr. Van Gelder and colleagues for pursuing
answers to some of these difficult issues in the RAte Control
Efficacy in permanent atrial fibrillation (RACE II) study.
Dr. Shelton concurs that the optimal approach to rate control
remains primarily based on clinical experience. He notes that 248
patients in the AFFIRM study crossed over to the rhythm-control
group, and 108 patients underwent ablation of the atrioventricular
junction (1). Many patients (approximately one-half) in the
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